Rus
Eng 
Congratulations to Prof. Yury Gogotsi for being elected to the MRS Board of Directors!
This position will allow him to help establish the direction of the societyas it strives to build “a dynamic, interactive, global community of materials researchers to advance technical excellence by providing a framework in which the materials disciplines can convene, collaborate, integrate and advocate.”
Yury Gogotsi is currently Distinguished University professor and Trustee Chair in the Department of Materials Science and Engineering at Drexel University and Director of A. J. Drexel Nanomaterials Institute.
Prof. Yury Gogotsi has been active in MRS for more than 20 years. He has been the organizer for various MRS symposia (2014 De Novo Carbon Nanomaterials II Symposium, 2009 Symposium on Materials Challenges Facing Electrical Energy Storage, and others), delivered numerous invited talks and was selected for the prestigious Fred Kavli Distinguished Lectureship in Nanotechnology in 2014. Much of his involvement was focused on students. He was the founding advisor of the MRS Student Chapter at Drexel. Moreover, he has advised some of the top students who have been awarded MRS Gold and Silver Graduate Student Awards, as well as two of three Arthur Nowick award winners. He served as chair of the MRS Student Chapters subcommittee in 2011-2015, increasing the total number of student chapters from about 60 to over 90, and introducing international chapters (16 total).
Source: http://www.mrs.org/elections-2015-results
Prof. Gogotsi′s Candidate’s Statement
MXenes potential applications include sensors, wound healing materials, and drug delivery systems. A recent study explored how different synthesis methods affect the safety and performance of MXenes. By comparing etching conditions and intercalation strategies, researchers discovered that fine-tuning the surface chemistry of MXenes plays a crucial role in improving biocompatibility. These results provide practical guidelines for developing safer MXenes and bring the field one step closer to real biomedical applications.
Exellent news, our joint patent application with Drexel University on highly porous MAX phase precursor for MXene synthesis published. Congratulations and thanks to all team involved!
Last Call! Have you submitted your abstract for IEEE NAP-2025 yet? Join us at the International Symposium on "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene-focused conference in Europe this year! Final Submission Deadline: May 15, 2025. Don’t miss this exclusive opportunity to showcase your research and engage with world leaders in the MXene field!
We are excited to announce the publication of latest review article on MXenes in Healthcare. This comprehensive review explores the groundbreaking role of MXenes—an emerging class of 2D materials—in revolutionizing the fields of medical diagnostics and therapeutics. Read the full article here: https://doi.org/10.1039/D4NR04853A.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Congratulations to all collaborators with this interesting joint work!
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.
